Seralutinib
As of the edition of 20 October 2026, Seralutinib is a small molecule: in active development; acts on CSF1R, KIT and PDGFRA and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Small molecule
- Registered trials
- 7, 0 stopped early
- Disease areas
- Lungs and airways; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 2 | 1 | 1 | 0 |
| Phase 3 | 3 | 1 | 1 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GB004 | Lead sponsor of trials | 2017 to now |